Horizon Therapeutics

Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on developing treatments for severe inflammation and autoimmune diseases. Its lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, aimed at treating conditions such as neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. The company is also advancing additional candidates, including VIB4920 for kidney transplantation rejection and Sjögren’s syndrome, as well as VIB7734 for cutaneous lupus erythematosus. Viela Bio has formed a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several countries in Asia. Founded in 2017, the company is dedicated to addressing unmet medical needs in the field of autoimmune disorders.

Curzion Pharmaceuticals is a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825).

Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntington's Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California.

Hyperion Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for orphan diseases, primarily focusing on urea cycle disorders (UCD) and hepatic encephalopathy. Headquartered in Brisbane, California, the company offers RAVICTI, a nitrogen-binding agent for the chronic management of UCD in both adult and pediatric patients, along with BUPHENYL and AMMONAPS therapies targeting specific UCD subtypes. Additionally, Hyperion is working on glycerol phenylbutyrate, an active pharmaceutical ingredient in RAVICTI, aimed at treating hepatic encephalopathy. Founded in 2006, Hyperion operates as a subsidiary of Horizon Pharma USA, Inc. since May 2015, and it remains committed to addressing the needs of underserved patient populations through its innovative treatments.

Vidara Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, developing, marketing, and distributing pharmaceutical products. Established in 2011 and headquartered in Alpharetta, Georgia, it offers Actimmune, a bioengineered form of interferon gamma-1b that enhances the human immune system. Actimmune is specifically indicated to reduce the frequency and severity of serious infections in patients with chronic granulomatous disease and to delay disease progression in those with severe, malignant osteopetrosis. Through a strategic approach that includes product acquisitions, sound marketing, and life cycle management, Vidara aims to create value in the pharmaceutical sector while addressing critical medical needs.